Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment

Last updated: June 7, 2021
Sponsor: Hunt Regional Medical Center
Overall Status: Active - Recruiting

Phase

1

Condition

Sars-cov-2

Treatment

N/A

Clinical Study ID

NCT04918914
Badar Kanwar
  • Ages 18-100
  • All Genders

Study Summary

Abstract Background: Clinicians in pulmonary critical care medicine and critical care medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is useful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3 (NLRP3).

Objective: To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by dapsone must be responsible for its observed preventive effects, functioning as a competitor.

Methods:

Patients who were on standard COVID-19 therapy are also after obtaining off label uses and explanation of side effects are started on dapsone 100-200 mg daily along with Cimetadine 400 mg three times daily.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. All, PCR confirmed cases of COVID-19

Exclusion

Exclusion Criteria:

  1. Only consenting consenting patients

Study Design

Total Participants: 100
Study Start date:
October 18, 2020
Estimated Completion Date:
December 31, 2021

Study Description

We are investigating in prospective ongoing non-randomized case study effects of addition of dapsone 100-200 mg daily in addition to standardized recommended treatment versus a a cohort of patient admitted at our institution since October 2020 versus a group that only received standardized treatment. Our primary out comes are decrease in FIO2 requirement leading to discharge from hospital and decrease in over all mortality between group treated with only standardized recommended treat versus group with addition of dapsone and cimetadine.

An objective criteria of improvement, was used for effectiveness of therapy.

A. a reduction in the FIO2 requirement and

B. a decrease in the progression of hypoxia. We treated the patients with standard COVID-19 ARDS treatment with dapsone 100 mg to target NLRP3 inflammasomes.

Connect with a study center

  • Hunt Regional Medical Center

    Greenville, Texas 75401
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.